Blog

Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Photo taken from thelancet.com

Jan 21, 2024, 07:38

Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Amalya Sargsyan, Medical Oncologist at the

“Narek Shaverdian, among other experts, shared new promising data from phase II study on the role of body radiation therapy (SBRT) addition to standard of care (SOC) for Non-small cell lung cancer (NSCLC) and Breast c-r oligoprogression.

SBRT shows promise as an addition to SOC in NSCLC, offering a fourfold increase in PFS. SBRT plus SOC group showed Progression-free survival (PFS) of 10.0 months versus 2.2 months in SOC-only group (HR 0.41, 95%CI 0.22-0.75; p=0.0039)
No significant PFS difference with SBRT plus SOC for breast cancer.

Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC? Make sure to read the full article for more details.”

Source: Amalya Sargsyan/LinkedIn

Amalya Sargsyan cancer Narek Shahverdian Non-small-cell lung cancer (NSCLC) OncoDaily Oncology Stereotactic body radiation therapy (SBRT) Yeolyan Hematology and Oncology Center

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage